Medicine guide
Cufence
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Trientine dihydrochloride
- Made by
- Univar Solutions BV
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Univar Solutions BV |
|---|---|
| Active substance | Trientine dihydrochloride |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A16A · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2019-07-25 |
| Last updated by the regulator | 2025-07-02 |
| EMA product number | EMEA/H/C/004111 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).